within Pharmacolibrary.Drugs.ATC.M;

model M01AB09
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.6,
    Cl             = 1.6666666666666667e-05,
    adminDuration  = 600,
    adminMass      = 100 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.015,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.013333333333333334,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>M01AB09</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Lonazolac is a non-steroidal anti-inflammatory drug (NSAID) of the anthranilic acid derivative class. It was used mainly for its analgesic and anti-inflammatory effects in conditions such as rheumatoid arthritis and other musculoskeletal disorders. Lonazolac is not widely approved or marketed today in most countries; its clinical use has essentially been discontinued.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for adult humans based on class characteristics due to lack of direct published data.</p><h4>References</h4><ol><li><p>Huber, R, et al., &amp; Petitet, A (1990). [Pharmacokinetics of the antirheumatic lonazolac-Ca in humans]. <i>Arzneimittel-Forschung</i> 40(8) 918–925. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/2242085/&quot;>https://pubmed.ncbi.nlm.nih.gov/2242085</a></p></li><li><p>Deneke, J, et al., &amp; Pässler, HH (1998). Transsynovial kinetics of lonazolac and its hydroxy metabolite in synovitis patients. <i>International journal of clinical pharmacology and therapeutics</i> 36(8) 418–424. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/9726694/&quot;>https://pubmed.ncbi.nlm.nih.gov/9726694</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end M01AB09;
